Roche's Tecentriq (atezolizumab) + Avastin (bevacizumab) Receive the EC's Approval for Unresectable Hepatocellular Carcinoma
Shots:
- The approval is based on P-III IMbrave150 study involves assessing of Tecentriq (atezolizumab- 1200mg) + Avastin (bevacizumab- 15 mg/kg) on day 1 of each 21-day cycle vs sorafenib (400mg- bid) on days 1-21 of each 21-day cycle in 501 patients in a ratio (2:1) with unresectable HCC- prior not treated with systemic therapies
- Result: reduction in the risk of OS (42%); reduction in the risk of disease worsening or death- PFS (41%); showed improvement in both OS and PFS; Grade 3–4 AEs (57% vs 55%)- published in the NEJM
- The approval follows an EMA’s CHMP positive opinion received in Sept’2020. The dual regimen also recently included as a class I- A recommendation by the ESMO for unresectable HCC- as well as by many clinical practice guidelines globally
Ref: Roche | Image: Roche
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com